During an immune response, activated cells of the immune system, such as T lymphocytes, undergo rapid expansion in order to fight infection or disease. Many interactions also occur between activated immune cells (e.g., T cell interactions with antigen-presenting cells and interactions between T cells themselves). These dynamic changes in cell number and cell-cell interactions are fundamental to regulating the effect and extent of the immune response. Understanding the mechanisms of immune cell activation, proliferation and regulation is key to the development of novel and effective anti-tumor immunotherapeutics.
Visualize and quantify immune cell interactions and proliferation in real time. Investigate the mechanisms of immune cell activation (proliferation), regulation and differentiation (clustering) inside your incubator and without the need to lift or label your cells.
Zumwalde NA, Domae E, Mescher MF, Shimizu Y. ICAM-1-dependent homotypic aggregates regulate CD8 T cell effector function and differentiation during T cell activation. J Immunol, 191(7):3681–93, 2013
Revealing the mechanisms of activated T cell aggregation using IncuCyte ZOOM® real time imaging and cell cluster analysis.
Zumwalde, N. A. The Role of ICAM-1 Mediated T cell:T cell Interactions on CD8+ T cell Effector Function and Differentiation. PhD Dissertation, University of Minnesota (2013)
Label-free detection of T cell aggregation. Activation of PBMCs with anti-CD3 antibody and IL-2 induces T cell aggregation or "clustering". User-friendly IncuCyte® software enables accurate quantification of cell clustering over time (blue mask).
Measure clustering in real time. Automated time-course analysis reveals treatment effects. Increasing the concentration of anti-CD3 antibody from 0.01 to 10 µg/ml in the presence of IL-2 (10 ng/ml) promotes T cell clustering
Real-time, label-free monitoring of PBMC proliferation. The IncuCyte® Live-Cell Analysis System automatically quantifies proliferation of PBMCs (yellow mask) activated with anti-CD3 antibody and IL-2 over a period of 144 hours. The full time course of PBMC proliferation is shown in the presence of anti-CD3 antibody and IL-2, anti-CD3 antibody alone, and in the absence of activators.